The cryptocurrency market is abuzz with speculation over potential 100x gains in 2025, with XRP and AurealOne (DLUME) emerging as key contenders. While XRP remains a staple in cross-border payments, the latter’s innovative skill-to-earn gaming model has captured attention as a sleeper hit. Both projects highlight diverging paths in crypto’s evolution, from utility-driven tokens to gamified ecosystems.
AurealOne, a Web3 gaming platform, aims to redefine competitive play by emphasizing skill over luck. Its native token, DLUME, enables staking, governance, and in-game rewards. At $0.0013, the token’s current price is modest, but its presale has already raised $3 million toward a $50 million target. The platform’s roadmap includes 60 games by September 2025, bolstered by a decentralized governance structure and a deep replay system for match analysis. Analysts note that its focus on skill-based mechanics and community ownership could position it as a leader in the Web3 gaming space [1].
XRP, meanwhile, continues to solidify its role in financial infrastructure. The token’s efficiency in cross-border transactions—handling thousands of transactions per second at low costs—has drawn institutional interest. Recent legal clarity and adoption by banks further its case as a stable, real-world asset. However, unlike AurealOne, XRP lacks the speculative allure of a gaming-first project, relying instead on established use cases [1].
The article also highlights other presale projects, including DexBoss (DEBO), a Solana-based analytics tool for traders, and World of Iselia (WOI), a blockchain RPG. MarmotsAI (MARMOTS) merges AI with blockchain for trading tools, while Doge Uprising (DUP) adds utility to meme coin culture. These projects underscore a broader trend: innovation in niche use cases, from AI-driven analytics to gamified staking, attracting investors seeking diversified exposure [1].
Investors are urged to approach presales cautiously. While AurealOne’s ambitious goals and XRP’s proven utility are compelling, risks remain. Regulatory shifts, market volatility, and project execution challenges could impact outcomes. The article emphasizes due diligence, advising readers to align investments with long-term strategies rather than short-term hype [1].
References:
[1] “Next Crypto to Explode: XRP Holds the Spotlight, But AurealOne Could Be the Hidden 100x Gem of 2025!” Cryptonewsland.com. https://cryptonewsland.com/next-crypto-to-explode-xrp-holds-the-spotlight-but-aurealone-could-be-the-hidden-100x-gem-of-2025/
The US dollar has rallied a bit during the early hours on Monday, breaking above the 200 day EMA, and now it looks like we’re trying to get to the 149 level. This is an area that I think we could be looking at as a major barrier and if we can break the 149 yen level, then 151 yen would be your next target. Short-term pullbacks are probably buying opportunities, but we do have a Bank of Japan meeting here in the next few days, so I’d be very cautious with this pair right now, although I still like the idea of buying.
AUD/USD Technical Analysis
The Australian dollar has fallen pretty significantly against the US dollar, but at this point in time, we are looking at the 50 day EMA sitting just below as well as the bottom of this channel. So, I think you’ve got a situation where the buyers may come back sooner or later, not necessarily right away, but if the pattern holds, we’re just simply going to test the lower part of the channel and see yet another bounce. I don’t really like shorting this pair until we get below the 200 day EMA, but truthfully buying it is a bit torturous as well. It’s just grinding ever so slowly higher.
For a look at all of today’s economic events, check out our economic calendar.
For the millions of Americans living with depression, there is no shortage of dietary supplements claiming to help. Some influencers are more than happy to spread the word.
Now, a new review of existing studies suggests that there is “substantive” evidence to support the benefits of only four supplements for depression: St. John’s wort, saffron, probiotics, and vitamin D.
Previous research on mental health supplements has typically focused on single products, says lead author Rachael Frost, PhD, a senior lecturer in health and social care at Liverpool John Moores University in England and a Western herbal practitioner. “This doesn’t allow us to look across the different products and see where the research is, and where the gaps are,” she says.
“We aimed to provide an overview of the clinical trials available for a large range of OTC products to show which products have the most evidence, and which have very little,” she says. “This was to help people make decisions about products they may want to try, and to help inform future research directions on this topic.”
“This research is very relevant, as so many people will try supplements before they ever even seek professional help,” says Alex Dimitriu, MD, a psychiatrist and sleep medicine physician and founder of Menlo Park Psychiatry and Sleep Medicine in Menlo Park, California.
4 Supplements Have the Most Proof They Can Help Depression
To understand the existing evidence on supplements for depression in adults under age 60, researchers conducted a “scoping review” of existing research They looked at 209 trials investigating 64 different types of supplements. For 41 of these supplements, researchers only found a single study.
Researchers found “substantive evidence” for just 4 of the 64 supplements, Dr. Frost says. “By substantive evidence, we mean that there were more than 10 trials for each product,” she explains.
Those supplements were:
St. John’s Wort St. John’s wort is an invasive, wild, flowering plant. The current review found a total of 37 trials on St. John’s wort, with more showing effects against placebo than no effects, with similar or better results than antidepressants, Frost says.
Saffron Eighteen trials on saffron showed similar effects to prescription antidepressants. Some trials showed greater effects than a placebo.
Probiotics In 16 trials, probiotics were shown to be more effective than placebo, Frost says. Probiotics may boost gut health and mood stability.
Vitamin D Tested in 14 trials, vitamin D was shown to be effective compared with a placebo, but Frost says it wasn’t effective compared with antidepressants. Vitamin D plays a role in thyroid regulation, sleep, and mood.
The evidence to support the positive impact of other supplements was limited, but did suggest possible benefits for depressive symptoms from the following:
The review yielded mixed results for: melatonin, magnesium, cinnamon, vitamin C, and several others.
“Our review really calls for carrying out more trials into those products with promising evidence,” Frost emphasizes. “It’s simply not a case of ‘Herbs or dietary supplements work or don’t work,’ but each product has levels of evidence with regards to their effectiveness. I would encourage people to look carefully into any product they are planning to take.”
The Study Has Limitations
Researchers didn’t assess the quality of the trials that were included, only the volume of clinical trials available, Frost says.
“This is because we were aiming to scope the literature and map out what evidence was available, rather than make definitive conclusions on each product,” she explains.
The review only included randomized controlled trials, considered the “gold standard of clinical evidence,” Frost adds. But some trials were large and well-conducted, while others were small pilot studies.
Another limitation is that the studies reviewed often included a variety of dosages of supplements and preparations, which makes it difficult to identify what may be most effective for individuals, she explains.
Most studies didn’t include the side effects of tested products. Frost says more research should report this information to help identify product safety issues.
Are Depression Supplements Safe?
The scoping review identified few side effects of the supplements studied, Frost says, “but people should always be cautious if they are currently taking medications or have other health conditions.”
The supplements are generally safe, but could potentially cause problems in high doses, says Robert G.G. Piccinini, DO, an osteopathic psychiatrist and president of the American Osteopathic Association.
For example, St. John’s wort may act on receptors for serotonin (a hormone associated with mood), which can affect sleep and appetite, he explains.
St. John’s wort can also interact with prescription antidepressants, Dr. Dimitriu says, so it’s a good idea to talk to your doctor before taking it, or any other supplement, for that matter.
If you want to try the four supplements that showed benefits for depression, don’t take them all at once. “A better decision would be adding one at a time to evaluate its individual effect,” Dr. Piccinini says.
Dietary supplements aren’t evaluated for safety and efficacy by the U.S. Food and Drug Administration (FDA) like prescription and over-the-counter medications are. In 2021, the FDA sent warning letters to 10 companies for “illegal selling” of products claiming to “cure, treat, mitigate, or prevent depression and other mental health disorders,” as there’s no evidence to support the claims.
Supplements Aren’t a Replacement for Mental Health Treatment
“I think the key is that the study recognizes the importance of combining psychological therapy with supplement or prescription medication,” Piccinini says.
Supplements shouldn’t be considered a replacement for mental health treatment for depression, Dimitriu says, as the condition can mask your thinking and outlook.
“It’s good to have outside guidance and oversight for the best outcomes” for depression, he says. “For anyone experiencing more debilitating symptoms of depression, I recommend against self-treatment, and instead working with a professional.”
Solana Price Prediction: Momentum Builds With Volume & OBV Confirmation
According to recent Solana news, SOL broke out decisively from a prior consolidation between $180–$185, anchored by rising On‑Balance‑Volume (OBV) and substantial inflowsThe market has reacted with a strong Solana price today near $190, clearing the 0.236 Fibonacci retracement and signaling renewed bullish intent.
Market watchers flag that once SOL clears $200 with strong volume, liquidity above that level is thin, often resulting in rapid price acceleration. Analysts predict targets between $250 and $336, depending on momentum sustainability. Recent Solana news highlights the launch of multiple SOL-based ETFs from VanEck and others, helping attract billions in institutional capital into the ecosystem.
Meanwhile, on-chain data confirms surging usage metrics weekly transaction volume, average TPS and TVL are hitting record levels. Solana now processes up to ~65,000 TPS, with millions of active addresses participating weekly. These fundamentals strengthen the Solana price prediction thesis and suggest it’s more than just a speculative spike.
But Many Investors Are Eyeing the Real Breakout: Remittix
While SOL’s price is consolidating, attention is shifting toward Remittix, a low‑priced Ethereum‑based token (RTX) quietly becoming the breakout DeFi payment project of 2025. Unlike Solana’s long-term roadmap uncertainty, Remittix is delivering real-world utility now:
Raised over $17.5 million via token sales (570M+ RTX sold at $0.0876)
Wallet beta launching September 15, offering full crypto wallet functionality
Up to 50% token bonus still available for early investors
Built for real use: freelancers and global workers using RTX for cross-border payouts
With product launches just weeks away and community momentum growing fast, Remittix is drawing comparisons to major layer‑1 tokens but with immediate utility and lower risk.
SOL Could Reach $1,000 by 2027. But Remittix Is Already Moving
If Solana continues to break through resistance and maintains its institutional inflow narrative, Solana price prediction models do show long-range targets of $300‑$420 by end‑2025, possibly extending toward $1,000 by 2027 in a broad market upswing. Yet it requires strong market conditions and sustained token demand.
Meanwhile, Solana news signals some consolidation ahead and smart capital is already rotating toward more tangible utility projects. Remittix, still sub‑$1, might just be the undervalued gem delivering real product traction before SOL even reaches $250.
Discover the future of PayFi with Remittix by checking out their project here:
La colangitis biliar primaria (CBP) es un trastorno autoinmunitario que afecta principalmente a mujeres y a personas que tuvieron asignación femenina cuando nacieron (AFAB, por sus siglas en inglés). LaCBP afecta el hígado y, si no se trata, puede causar problemas graves, tales como cirrosis e insuficiencia hepática.
Las buenas noticias son que hay tratamientos disponibles que podrían ser útiles para reducir los síntomas y frenar el progreso de la enfermedad.
Nos comunicamos conNancy Reau, M.D., directora adjunta de trasplantes de órganos sólidos y jefa de la sección de hepatología del centro médico de Rush University, para obtener información verificada y consejos para controlar la CBP.
¿Qué es la CBP?
La colangitis biliar primaria (CBP) ocurre cuando tu propio sistema inmunitario empieza a reaccionar en tu contra y ataca conductos biliares pequeños en el hígado. Esto causa una acumulación de bilis y un bloqueo del flujo biliar (colestasis), lo cual hace que los conductos biliares se inflamen y que las células hepáticas se deterioren. Este deterioro causa cicatrices, lo cual se denomina fibrosis. Con el tiempo, el tejido de las cicatrices reemplaza al tejido saludable (lo cual se denomina cirrosis) y los ductos biliares se deterioran, lo cual causa daño al hígado que empeora con el tiempo.
¿Cuáles son los factores de riesgo de la CBP?
No comprendemos todos los factores, pero antecedentes familiares de CBP o de trastornos inmunitarios son probablemente los factores más importantes. Tradicionalmente se pensaba que la CBP era exclusivamente un trastorno que solo afectaba a mujeres de raza blanca de mediana edad, pero estamos encontrando CBP en hombres, en personas de varias razas y también en personas jóvenes y de edad avanzada. Sin embargo, la CBP todavía es más común en mujeres que en hombres.
¿Cuáles son los síntomas de la CBP?
Muchas personas con CBP no tienen síntomas que sean específicos para ese trastorno, y cuando los tienen, los síntomas varían para cada persona. Los síntomas iniciales más frecuentes son comezón (denominada prurito) y fatiga. Personas con CBP también podrían padecer dolor abdominal; oscurecimiento de la piel; protuberancias pequeñas amarillas o blancas bajo la piel (xantomas) o alrededor de los ojos (xantelasmas); sequedad en la boca y los ojos; y dolores de los huesos, músculos y articulaciones.
Otras señales y síntomas podrían incluir al síndrome seco, que es una sequedad crónica de los ojos y la boca y niveles altos de colesterol.
Muchas personas que padecen CBP no tienen síntomas aparte de la comezón y la fatiga en las primeras etapas del trastorno. Si tienes síntomas de CBP deberías hablar sobre eso con tu proveedor de atención médica (HCP, por sus siglas en inglés).
¿Cómo se diagnostica la CBP?
Podría ser difícil para proveedores de atención médica emitir un diagnóstico de CBP inicialmente puesto que el trastorno puede presentar síntomas no específicos tales como comezón y fatiga. Pero hay varias formas en las que se puede diagnosticar la CBP.
Pruebas de sangre pueden detectar mayores niveles de una enzima llamada fosfatasa alcalina y bilirrubina, así como un indicador inmunitario llamado anticuerpo antimitocondrial.
La CBP se diagnostica cuando pruebas de sangre de una persona muestran niveles elevados de fosfatasa alcalina debido a cambios del flujo biliar (denominados colestasis) así como la presencia de anticuerpos antimitocondriales.
Si los resultados de las pruebas de sangre son ambiguos, una biopsia hepática u otras pruebas del sistema inmunitario podrían realizarse para diagnosticar el trastorno si hay alguna preocupación de insuficiencia hepática (debido a niveles altos de bilirrubina).
¿Cuáles son los tratamientos para la colangitis biliar primaria?
Hay algunos medicamentos aprobados que son útiles para controlar la CBP. La mayoría de planes terapéuticos empiezan con la terapia de primera línea, lo que quiere decir que es el primer medicamento que tu proveedor de atención médica probará. Tu doctor comúnmente esperará ver una mejora en las pruebas de sangre para confirmar que el medicamento funcione. Si hay una reacción bioquímica inadecuada a la terapia de primera línea después de 12 meses, tu doctor podría considerar opciones terapéuticas adicionales. En algunos casos, en función de criterios clínicos y de tendencias individuales de las pruebas de sangre, se podrían considerar otras terapias a los 6 y 12 meses. Los tratamientos de segunda línea, que pueden usarse en combinación con opciones de primera línea o individualmente, han demostrado mejoras de los niveles de las enzimas hepáticas y podrían ser útiles para aliviar los síntomas, tales como la comezón. Tu proveedor de atención médica siempre debería tomar decisiones terapéuticas en función de tu perfil clínico específico.
¿Hay cambios del estilo de vida que podrían ser útiles para mantener tu salud si vives con CBP?
Cada paciente debería hablar sobre los métodos terapéuticos y de atención con su proveedor médico, pero, en general, motivamos a personas con CBP a que se enfoquen en un estilo de vida saludable, incluyendo ejercicio en forma regular y una dieta rica en alimentos integrales, fibra y proteínas magras. Las personas que viven con CBP también deberían concentrarse en su salud ósea porque osteopenia y osteoporosis son más frecuentes en personas con CBP. También se recomienda dejar de fumar y limitar el consumo de alcohol.
¿Qué consejos son útiles para manejar tu salud si tienes CBP?
Primero, debes cuidar tu salud. Conoce qué medicamento tomas y si funciona. Esto realmente es difícil para la CBP porque han habido cambios significativos en lo que se considera una “buena reacción al tratamiento”. Es decir, asegúrate que tú y tu doctor tengan información actualizada. Cerciórate de que encuentres un proveedor médico que escuche lo que dices y con quien te puedas comunicar efectivamente en lo que se refiere a las metas terapéuticas. Tus pruebas hepáticas serán útiles para determinar si el tratamiento funciona, así que asegúrate de entender qué niveles son buenos para ti y para tu proveedor de atención médica.
También deberías hacer que se evalúe tu función tiroidea una vez al año y monitorear tu salud ósea debido a un mayor riesgo de osteopenia y osteoporosis.
Vivir con CBP también puede ser difícil desde el punto de vista emocional. Así que es importante tener un buen sistema de apoyo para cuidar tu salud mental. Además de familiares y amigos, grupos de concientización de pacientes y comunidades virtuales pueden proporcionar consuelo, consejos y apoyo emocional.
Por último, habla con tus familiares. Aunque esto no se establece firmemente en las pautas actuales, recomendamos que propongas a tus familiares de primer grado (hermanas, hijas y madres) que hablen con tu proveedor de atención médica para que las examine porque sabemos que tienen un mayor riesgo. Aunque la CBP es menos frecuente en los hombres, ellos también deberían hablar con sus proveedores de atención médica si tienen síntomas.
Este recurso educativo se preparó con el apoyo de Gilead.
Tokenization platform Brickken has partnered with decentralized lending protocol Credefi to launch a permissionless, peer-to-peer RWA lending system, enabling users to borrow and lend USDC using tokenized real-world assets (RWAs) as collateral. The integration allows borrowers to set custom loan terms—including interest rates and durations—without custodial intermediaries or traditional banking systems [1]. This collaboration marks a pivotal step in expanding DeFi’s utility for RWAs, moving beyond mere tokenization to unlocking liquidity and autonomous lending.
Edwin Mata, Brickken’s CEO, highlighted that the initiative shifts tokenization from a static representation of assets to a dynamic tool for generating liquidity and decentralized financing. “Tokenization is about unlocking utility, liquidity, and autonomy,” Mata stated, emphasizing that the partnership leverages DeFi to create actionable use cases for RWAs [2]. Ludovico Rossi, Brickken’s chief risk officer, noted that the integration fills a critical gap in the RWA ecosystem by introducing a liquidity layer through DeFi. While issuance and compliance have advanced, the alignment of issuance, compliance, and DeFi now forms a foundation for scaling tokenized assets [2].
The non-custodial lending system operates via Credefi’s decentralized infrastructure, allowing users to directly collateralize RWAs and access liquidity. This approach aligns with DeFi’s broader goal of reducing reliance on centralized entities while enhancing transparency and efficiency. By removing gatekeeping mechanisms, the system democratizes access to RWA-based lending, enabling a wider range of participants to engage in the ecosystem [1].
Despite its innovation, analysts caution that RWA lending is unlikely to disrupt traditional financial markets in the near term. Instead, it offers an alternative for asset holders to leverage the perceived value of their RWAs for loans, bypassing conventional collateral requirements. This model could appeal to individuals and institutions seeking flexible, decentralized financing, particularly in sectors like real estate and infrastructure where tokenized RWAs are gaining traction [2].
The partnership reflects growing momentum in bridging traditional and decentralized finance. By integrating RWAs into DeFi protocols, Brickken and Credefi aim to enhance asset liquidity and drive tokenized asset adoption. Challenges persist, however, including regulatory scrutiny and the need for market education as blockchain ecosystems evolve to accommodate physical assets [1].
Platinum price ended the correctional trading by testing the extra support at $1381.00, forming a confirmation key for the continuation of the positive continuation, attacking the barrier at $1420.000 level, to find an exit for resuming the bullish attempts.
Stochastic begins to provide positive momentum by its repeated stability above 20 level, which makes us wait for breaching the current barrier and holding above it, to ease the mission of targeting $1458.00 level, and surpassing it will provide a chance for achieving new gains that might extend to $1480.00 and $1507.00.
The expected trading range for today is between $1390.00 and $1458.00
Arkadia, an Australian beverage company, has recently launched a new Matcha Latte product line featuring two distinct flavors: Original and Strawberry. The Original flavor offers a rich, authentic matcha taste, while the Strawberry flavor introduces a refreshing fruity twist. Both of these beverage options are 99% fat-free when mixed with water and are free from artificial colors, sweeteners, and preservatives.
A Fresh Approach to Matcha
Ramona Culda, the head of brands at Maltra Foods, Arkadia’s parent company, explained that their new product line aims to present matcha in a more approachable manner. Matcha is often associated with a bitter or grassy taste, which can be off-putting for some. To combat this, Arkadia has developed a smooth, creamy version of the traditionally bitter tea that can be enjoyed at any time of day.
Culda emphasizes, “We’ve created a blend that is incredibly sippable, with no compromise on flavor and definitely without the characteristic bitterness of matcha.”
Availability and Pricing Details
The Arkadia Matcha Latte range is available in 220g canisters and in packs of eight single-serve sachets. These products are priced at $7.50 and $0.95 respectively and can be purchased from Coles and Woolworths stores across the nation.
Questions & Answers
What flavors does the Arkadia Matcha Latte range include? The Arkadia Matcha Latte range includes two flavors: Original and Strawberry.
How has Arkadia made matcha more approachable with their new product? Arkadia has created a smooth and creamy version of traditionally bitter matcha, making it a refreshing beverage that can be enjoyed at any time of day, while maintaining the authentic matcha flavor.
Where can the Arkadia Matcha Latte range be purchased, and what is the cost? The Arkadia Matcha Latte range is available at Coles and Woolworths stores nationwide. The 220g canister is priced at $7.50, and the eight-pack of single-serve sachets costs $0.95.
Bitcoin’s tightening range trading signals a possible range expansion in the next few days.
Select altcoins also face selling pressure, but remain above their near-term support levels.
Bitcoin BTCUSD continues to sell off at the $120,000 level, but the repeated retest of a resistance level tends to weaken it. If buyers do not cede much ground to the bears, it improves the prospects of BTC hitting a new all-time high above $123,218.
Fundstrat head of research Tom Lee said in an interview with CNBC that BTC could soar to $200,000 to $250,000 over the next few months. At that price, Lee believes BTC would be valued at 25% of the size of the gold market.
BTC’s consolidation seems to have driven investors into Ether ETHUSD, which is charging higher. Spot ETH exchange-traded funds have recorded a 16-day inflow streak, boosting the cumulative net inflows from $4.25 billion on July 2 to $9.33 billion on Friday.
Could BTC break above the overhead resistance, or will it remain in a range? Could select altcoins continue their strong run? Let’s analyze the charts of the top 10 cryptocurrencies to find out.
S&P 500 Index price prediction
The S&P 500 Index (SPX) continued its march toward the target objective of 6,500, indicating sustained demand at higher levels.
The upsloping moving averages signal that bulls remain in control, but the overbought level on the relative strength index (RSI) suggests the rally may be getting overheated. That increases the risk of possible consolidation or correction in the near term.
If the price turns down but bounces off the 20-day simple moving average (6,283), it indicates that the sentiment remains positive. That increases the likelihood of a rally to 6,500. Sellers will have to yank the price below the 50-day SMA (6,099) to gain the upper hand.
US Dollar Index price prediction
The US Dollar Index (DXY) is trying to sustain above the 50-day SMA (97.68), indicating that the bulls are attempting to form a higher low.
If they succeed, the index could soar to 100.54 and then to the 102 level. Sellers are expected to pose a strong challenge at 102.
On the contrary, the failure to maintain the price above the 50-day SMA indicates that bears remain in control. The bears will then try to strengthen their position by pulling the price below 97.10. If they manage to do that, the index risks a retest of the crucial support at 96.37.
Bitcoin price prediction
BTC slipped below the 20-day SMA ($117,867) on Friday, but the long tail on the candlestick shows solid buying at lower levels.
The bulls are trying to drive the BTCUSDT pair above the $120,000 to $123,218 resistance zone. If they manage to do that, the pair is likely to accelerate toward $135,728 and later to the pattern target of $150,000.
Time is running out for the bears. If they want to make a comeback, they will have to swiftly pull the price below the $110,530 support. That may trap the aggressive bulls, resulting in a long liquidation. The pair may then tumble to psychological support at $100,000.
Ether price prediction
Ether surged above the $3,745 resistance on Sunday, but the bulls are struggling to hold on to the higher levels.
Sellers will try to pull the price below $3,745. If they manage to do that, the ETHUSDT pair could slump to the 20-day SMA ($3,423). Buyers are expected to defend the 20-day SMA because a break below it signals the start of a deeper correction.
Conversely, if the price rebounds off the $3,745 level or the 20-day SMA with strength, it indicates buying on dips. The bulls will then again try to drive the pair to $4,094. If the $4,094 level is taken out, the pair could skyrocket toward $4,868.
XRP price prediction
XRP’s XRPUSD pullback from $3.66 found support at the 20-day SMA ($3.10) on Thursday, indicating buying on dips.
The bulls tried to push the price toward $3.66 but are facing significant resistance from the bears. If the price continues lower and breaks below the 20-day SMA, it suggests the start of a deeper correction. The XRPUSDT pair may drop to $3 and later to $2.80.
Contrarily, if the price rebounds off the 20-day SMA, it signals that the bulls are fiercely defending the level. The pair could then rally to $3.66. A break and close above $3.66 could catapult the pair to $4 and, after that, to $4.86.
BNB price prediction
BNB BNBUSD turned down from $809 on Wednesday, but the bears could not sustain the price below $761. That suggests the bulls have flipped the level into support.
Buyers thrust the price above $809 on Sunday, starting the next leg of the uptrend. The BNBUSDT pair could run toward $900 and thereafter to the psychological level of $1,000.
Although the trend remains up, the deeply overbought level on the RSI suggests the rally is due for a consolidation or correction in the near term. The first sign of weakness will be a break and close below $793. That suggests profit-booking at higher levels. The pair may then descend to $761, where the buyers are expected to step in.
Solana price prediction
Solana’s SOLUSD pullback from $209 on Wednesday stalled at the 20-day SMA ($176) on Friday, indicating demand at lower levels.
The bulls are trying to push the price to $209 but are facing selling at higher levels. If buyers overcome the barrier at $209, the SOLUSDT pair could rally to $240 and eventually to $260. There is minor resistance at $220, but it is likely to be crossed.
This positive view will be invalidated in the short term if the price turns down and breaks below the 20-day SMA. The pair may then descend to the 50-day SMA ($160). That points to a possible range-bound action between $110 and $209.
Dogecoin price prediction
Dogecoin DOGEUSD turned up from the 20-day SMA ($0.22) on Friday, indicating demand at lower levels.
The relief rally is facing selling near $0.26, indicating that the bears are active at higher levels. If the price plummets below the 20-day SMA, the DOGEUSDT pair may remain inside the large $0.14 to $0.29 range for a few more days.
Buyers will have to propel the price above $0.29 to seize control. If they manage to do that, the pair could start a new up move to $0.35 and then to the pattern target of $0.44.
Cardano price prediction
Cardano’s (ADA) bounce off the 20-day SMA ($0.78) is facing selling at the overhead resistance of $0.86.
The upsloping 20-day SMA and the RSI in the positive territory indicate an advantage to the bulls. A break above $0.86 could push the ADAUSDT pair to $0.94. Sellers will try to halt the up move at $0.94, but if the bulls prevail, the pair could soar to $1.02 and then to $1.17.
The short-term advantage will tilt in favor of the bears if the price continues lower and plummets below the 20-day SMA. That suggests profit-booking on rallies. The pair may then decline to the 50-day SMA ($0.67).
Hyperliquid price prediction
Hyperliquid (HYPE) rebounded off the support line of the ascending channel pattern on Friday, indicating buying on dips.
There is resistance at the 20-day SMA ($45.06), but if the bulls overcome it, the HYPE/USDT pair could rise to $48 and subsequently to $50. Sellers are expected to mount a strong defense at $50.
Conversely, if the price turns down from the 20-day SMA, the bears will try to pull the pair below the support line. If they succeed, the pair may start a deeper correction toward $36 and then $32.
This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.
The NFT market experienced a dramatic resurgence in July 2025, with trading volumes and market capitalization surging as blue-chip collections like CryptoPunks drove renewed investor interest. Total NFT sales reached $221 million during the month, a 40% week-on-week increase, while the overall market capitalization climbed to $7 billion—a 94% jump from previous levels. CryptoPunks, the iconic 2017-launched NFT series, emerged as the market’s focal point, with their floor price surpassing $200,000 for the first time since mid-2024. This milestone marked a 15.9% rise within 24 hours on July 22, accompanied by 83 new purchases in a single day [2]. The collection’s value surged 590% month-on-month, reinforcing its status as the most sought-after digital asset in the NFT space [1].
The market’s revival was further amplified by increased activity across other high-profile projects. Pudgy Penguins outperformed the Bored Ape Yacht Club in market capitalization, while Ethereum-related NFT sales alone approached $160 million in the week ending July 28 [5]. OpenSea and other platforms reported a 18% weekly increase in trading volume, driven by cross-chain demand for Solana and Bitcoin-based NFTs [7]. Analysts attributed the surge to speculative trading and a broader optimism around Ethereum’s dominance in NFT transactions, as ETH remained the primary settlement asset [3].
Despite the robust figures, the market’s sustainability remains a topic of debate. The 94% increase in market capitalization followed a prolonged consolidation phase, raising concerns about whether the rally is fueled by short-term speculation rather than institutional adoption. However, the sheer scale of the July rebound suggests a reawakening of NFTs as both an investment class and a cultural asset. DappRadar analysts noted that “the NFT market hasn’t seen this level of energy in months,” drawing parallels to past booms while cautioning about potential regulatory adjustments [4].
CryptoPunks’ resurgence highlights the enduring appeal of early NFT projects. Their floor price crossing $200,000 not only reflects renewed liquidity but also cements their role as a benchmark for NFT valuation. Collectors and traders view the collection as a “safe haven” within the broader market, which has historically experienced volatility [2]. The performance of other blue-chip collections, such as f(x) wstETH, further underscores a shift in investor strategies toward established projects.
Looking ahead, the market’s trajectory will likely hinge on regulatory clarity and technological advancements, particularly Ethereum’s ongoing upgrades. While the July data paints a picture of a market in revival, the balance between speculative momentum and long-term adoption will remain critical. For now, CryptoPunks and their peers have reasserted their dominance, signaling a renewed phase of growth for the NFT sector.
[2] [CryptoPunks NFT Floor Price Surges Past $200K] (https://blockchain.news/flashnews/cryptopunks-nft-floor-price-surges-past-200k-trading-insights-and-market-impact)
[3] [The market value has doubled, the floor price and trading …] (https://www.panewslab.com/en/articles/9hdx7t2n)
[4] [Top NFT Activity Of The Week: CryptoPunks And Pudgy …] (https://blockchainreporter.net/top-nft-activity-of-the-week-cryptopunks-and-pudgy-penguins-secure-top-positions/)
[5] [Ethereum NFT Sales Near $160 Million in Recent Week] (https://www.binance.com/en/square/post/27510488967850)
[7] [Live Best Meme Coins Updates Today] (https://bitcoinist.com/meme-coins-live-news-july-28-2025/)
